Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.78 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | NPY1R | P25929 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | NPY2R | P49146 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16609165 | 1.00 | ADORA1 (0.78) | ADORA1SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL3395259 | 1.00 | ADORA1 (0.78) | ADORA1SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL24390241 | 1.00 | ADORA1 (0.78) | ADORA1SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL28593310 | 0.88 | ADORA1 (1.00) | ADORA1SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL20626400 | 0.88 | SLC29A1 (0.74) | ADORA1SLC29A1ADORA3ADORA2A | |
| SCHEMBL19583087 | 0.88 | SLC29A1 (0.74) | ADORA1SLC29A1ADORA3ADORA2A | |
| SCHEMBL17825976 | 0.88 | SLC29A1 (0.74) | ADORA1SLC29A1ADORA3ADORA2A | |
| SCHEMBL20626401 | 0.88 | SLC29A1 (0.74) | ADORA1SLC29A1ADORA3ADORA2A | |
| SCHEMBL640373 | 0.88 | SLC29A1 (0.74) | ADORA1SLC29A1ADORA3ADORA2A | |
| SCHEMBL640372 | 0.88 | SLC29A1 (0.74) | ADORA1SLC29A1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3912973-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3536687-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20200347068-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-10787455-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3536687-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190084990-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9670214-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3150593-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150094275-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | US | disclosed |
| US-8921336-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2011-12-22 | — | — | US | disclosed |
| WO-2009073153-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INSTITUTE (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | BCR, ABL1, MCL1 | ADORA1 4855/4885SLC29A1 4421/4885LMNA 4176/4885 |
| US-20150094275-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ADORA1 4792/4885SLC29A1 3657/4885LMNA 3806/4885 |
| US-20190084990-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ADORA1 4804/4885SLC29A1 3315/4885LMNA 3713/4885 |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ADORA1 4847/4885SLC29A1 4377/4885LMNA 4069/4885 |
| US-20200347068-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ADORA1 4855/4885SLC29A1 4421/4885LMNA 4176/4885 |
| US-20110312908-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | BCR, ABL1, MCL1 | ADORA1 4837/4885SLC29A1 4321/4885LMNA 3841/4885 |
| US-10787455-B2 | Small molecule myristate inhibitors of BCR-ABL and methods of use | BCR, ABL1, MCL1 | ADORA1 4804/4885SLC29A1 3315/4885LMNA 3713/4885 |
| US-20170349595-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND ABL AND METHODS OF USE | BCR, ABL1, ABL2 | ADORA1 4769/4885SLC29A1 3185/4885LMNA 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.